ABSTRACT
Objectives: To determine the efficacy of craniofacial resection and proton radiation for the management of esthesioneuroblastoma (ENB). Design: A retrospective chart review was performed of all patients presenting with ENB and completely managed at the Massachusetts General Hospital (MGH) and the Massachusetts Eye and Ear Infirmary (MEEI) from 1997 to 2006. Setting: A tertiary referral center. Main Outcome Measures: Disease-free and overall survival. Participants: All patients presenting with ENB and completely managed at the MGH and the MEEI from 1997 to 2006. Results: Ten patients were identified with a median follow-up time of 52.8 months. Average age at presentation was 45 years. Nasal obstruction was the most common presenting symptom. Three patients presented with Kadish stage B disease and seven with stage C. No patient had evidence of cervical or metastatic disease at presentation. Seven patients were treated with craniofacial resections (CFR) followed by proton beam radiation with or without chemotherapy. Three patients were treated with initial chemotherapy with no response. They subsequently underwent CFR followed by proton beam radiation. The 5-year disease-free and overall survival rates were 90% and 85.7%, respectively, by Kaplan-Meier analysis. No patient suffered any severe radiation toxicity. Conclusion: ENB can be safely and effectively treated with CFR followed by proton beam irradiation. Proton irradiation may be associated with less toxicity than photon irradiation. The role of chemotherapy remains unclear.
KEYWORDS
Esthesioneuroblastoma - proton radiation - craniofacial resection
REFERENCES
1
Berger L, Luc R, Richard D.
L'esthésioneuroépithéliome olfactif.
Bull Assoc Fr Etude Cancer.
1924;
13
410-421
2
Bhattacharyya N, Thornton A F, Joseph M P, Goodman M L, Amrein P C.
Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: results in 9 cases.
Arch Otolaryngol Head Neck Surg.
1997;
123
34-40
3
Dulguerov P, Allal A S, Calcaterra T C.
Esthesioneuroblastoma: a meta-analysis and review.
Lancet Oncol.
2001;
2
683-690
4
Levine P A, Gallagher R, Cantrell R W.
Esthesioneuroblastoma: reflections of a 21-year experience.
Laryngoscope.
1999;
109
1539-1543
5
Nishimura H, Ogino T, Kawashima M et al..
Proton-beam therapy for olfactory neuroblastoma.
Int J Radiat Oncol Biol Phys.
2007;
68
758-762
6
Simon J H, Zhen W, McCulloch T M et al..
Esthesioneuroblastoma: the University of Iowa experience 1978–1998.
Laryngoscope.
2001;
111
488-493
7
Dias F L, Sa G M, Lima R A et al..
Patterns of failure and outcome in esthesioneuroblastoma.
Arch Otolaryngol Head Neck Surg.
2003;
129
1186-1192
8
Dulguerov P, Calcaterra T.
Esthesioneuroblastoma: the UCLA experience 1970–1990.
Laryngoscope.
1992;
102
843-849
9
Foote R L, Morita A, Ebersold M J et al..
Esthesioneuroblastoma: the role of adjuvant radiation therapy.
Int J Radiat Oncol Biol Phys.
1993;
27
835-842
10
Irish J, Dasgupta R, Freeman J et al..
Outcome and analysis of the surgical management of esthesioneuroblastoma.
J Otolaryngol.
1997;
26
1-7
11
Suit H, Goldberg S, Niemierko A et al..
Proton beams to replace photon beams in radical dose treatments.
Acta Oncol.
2003;
42
800-808
12
Gay E, Sekhar L N, Rubinstein E et al..
Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients.
Neurosurgery.
1995;
36
887-896
discussion 896-887
13
Munzenrider J E, Liebsch N J.
Proton therapy for tumors of the skull base.
Strahlenther Onkol.
1999;
175(suppl 2)
57-63
14
Pommier P, Liebsch N J, Deschler D G et al..
Proton beam radiation therapy for skull base adenoid cystic carcinoma.
Arch Otolaryngol Head Neck Surg.
2006;
132
1242-1249
15
Kaplan E M.
Nonparametric estimation from incomplete observation.
J Am Stat Assoc.
1958;
53
457-481
16
Kadish S, Goodman M, Wang C C.
Olfactory neuroblastoma: a clinical analysis of 17 cases.
Cancer.
1976;
37
1571-1576
17
Levine P A, Scher R L, Jane J A et al..
The craniofacial resection—eleven-year experience at the University of Virginia: problems and solutions.
Otolaryngol Head Neck Surg.
1989;
101
665-669
18
Rosenthal S J, Gall K P, Jackson M, Thornton Jr A F.
A precision cranial immobilization system for conformal stereotactic fractionated radiation therapy.
Int J Radiat Oncol Biol Phys.
1995;
33
1239-1245
19
Urie M, Goitein M, Wagner M.
Compensating for heterogeneities in proton radiation therapy.
Phys Med Biol.
1984;
29
553-566
20 National Cancer Institute .Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program Web site. Available at: http://ctep.cancer.gov/reporting/ctc.html
21
Goldsweig H G, Sundaresan N.
Chemotherapy of recurrent esthesioneuroblastoma: case report and review of the literature.
Am J Clin Oncol.
1990;
13
139-143
22
McElroy Jr E A, Buckner J C, Lewis J E.
Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.
Neurosurgery.
1998;
42
1023-1027
discussion 1027-1028
23
Resto V A, Eisele D W, Forastiere A et al..
Esthesioneuroblastoma: the Johns Hopkins experience.
Head Neck.
2000;
22
550-558
24
Lund V J, Howard D, Wei W, Spittle M.
Olfactory neuroblastoma: past, present, and future?.
Laryngoscope.
2003;
113
502-507
25
Polonowski J M, Brasnu D, Roux F X, Bassot V.
Esthesioneuroblastoma: complete tumor response after induction chemotherapy.
Ear Nose Throat J.
1990;
69
743-746
26
Morita A, Ebersold M J, Olsen K D et al..
Esthesioneuroblastoma: prognosis and management.
Neurosurgery.
1993;
32
706-714
discussion 714-715
27
Argiris A, Dutra J, Tseke P, Haines K.
Esthesioneuroblastoma: the Northwestern University experience.
Laryngoscope.
2003;
113
155-160
28
Constantinidis J, Steinhart H, Koch M et al..
Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975–2000.
Otolaryngol Head Neck Surg.
2004;
130
567-574
29
McLean J N, Nunley S R, Klass C et al..
Combined modality therapy of esthesioneuroblastoma.
Otolaryngol Head Neck Surg.
2007;
136
998-1002
30
Loy A H, Reibel J F, Read P W et al..
Esthesioneuroblastoma: continued follow-up of a single institution's experience.
Arch Otolaryngol Head Neck Surg.
2006;
132
134-138
31
Austin J R, Cebrun H, Kershisnik M M et al..
Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the M.D. Anderson cancer center.
Skull Base Surg.
1996;
6
1-8
32
Wade Jr P M, Smith R E, Johns M E.
Response of esthesioneuroblastoma to chemotherapy: report of five cases and review of the literature.
Cancer.
1984;
53
1036-1041
33
Hwang S K, Paek S H, Kim D G et al..
Olfactory neuroblastomas: survival rate and prognostic factor.
J Neurooncol.
2002;
59
217-226
Anthony C NicholsM.D.
Resident, Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary
243 Charles Street, Boston, MA 02114
eMail: Anthony_Nichols@meei.harvard.edu